Scrip
UCB lowers forecast as Keppra falls
30 April 2009
Simon Varcoe
Please Login to read the full article.
30 April 2009
Simon Varcoe
UCB has lowered its full-year revenue guidance from €3.3 billion to between €3.1 billion and$3.3 billion after its sales decreased in the first-quarter.
The Belgian biopharmaceutical company attributed the decline to lower net sales in the US, where the epilepsy drug Keppra (levetiracetam)...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
